<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03966911</url>
  </required_header>
  <id_info>
    <org_study_id>CIP324</org_study_id>
    <nct_id>NCT03966911</nct_id>
  </id_info>
  <brief_title>Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics</brief_title>
  <official_title>Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with&#xD;
      an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, prospective, single-sample correlational design without&#xD;
      controls. The purpose of this study is to demonstrate the performance of the Guardian™ Sensor&#xD;
      (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7&#xD;
      days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">May 13, 2020</completion_date>
  <primary_completion_date type="Actual">May 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Readings Within 20% Agreement</measure>
    <time_frame>7 days (170 hours)</time_frame>
    <description>Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values &lt; 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">335</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subjects with diabetes wearing Guardian™ Sensor (3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter</intervention_name>
    <description>Continuous Glucose Monitoring and frequent sample testing</description>
    <arm_group_label>Subjects with diabetes wearing Guardian™ Sensor (3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individual is 2 - 80 years of age at time of enrollment&#xD;
&#xD;
          2. A clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as&#xD;
             determined via medical record or source documentation by an individual qualified to&#xD;
             make a medical diagnosis&#xD;
&#xD;
          3. Adequate venous access as assessed by investigator or appropriate staff&#xD;
&#xD;
          4. Subjects participating in the high and low glucose challenges must have an insulin&#xD;
             carbohydrate ratio(s) and insulin sensitivity ratio. Subjects without ratios may&#xD;
             participate under observation only&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement&#xD;
             as assessed by a qualified individual.&#xD;
&#xD;
          2. Subject has any unresolved adverse skin condition in the area of sensor or device&#xD;
             placement (e.g., psoriasis, rash, Staphylococcus infection)&#xD;
&#xD;
          3. Subject is actively participating in an investigational study (drug or device) wherein&#xD;
             they have received treatment from an investigational study (drug or device) in the&#xD;
             last 2 weeks&#xD;
&#xD;
          4. Subject is female and has a positive pregnancy screening test&#xD;
&#xD;
          5. Female of child bearing age and who is sexually active should be excluded if she is&#xD;
             not using a form of contraception deemed reliable by investigator&#xD;
&#xD;
          6. Subject is female and plans to become pregnant during the course of the study&#xD;
&#xD;
          7. Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment&#xD;
&#xD;
          8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6&#xD;
             months prior to enrollment.&#xD;
&#xD;
          9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
         10. Subject has a history of a seizure disorder&#xD;
&#xD;
         11. Subject has central nervous system or cardiac disorder resulting in syncope&#xD;
&#xD;
         12. Subject has a history of myocardial infarction, unstable angina, coronary artery&#xD;
             bypass surgery, coronary artery stenting, transient ischemic attack (TIA),&#xD;
             cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm&#xD;
             disturbances or thromboembolic disease&#xD;
&#xD;
         13. Subject has a hematocrit (Hct) lower than the normal reference range (please note that&#xD;
             patients may use prior blood draw from routine care as long as done within 6 months of&#xD;
             screening and report of lab placed with subject source documents)&#xD;
&#xD;
         14. Subject has a history of adrenal insufficiency&#xD;
&#xD;
         15. Subject is a member of the research staff involved with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMCR Institue</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Diabetes Research Institute</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center - Adults</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes (Pediatric)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDERC</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Rochester MN)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes &amp; Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virgina</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainer Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03966911/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT03966911/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>335 subjects (188 adult subjects and 147 pediatric subjects) consented and enrolled in the overall study. Of them, 311 subjects (169 adult subjects and 142 pediatric subjects) were eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adult Subjects (Age 18-80) With Diabetes Wearing Guardian™ Sensor (3)</title>
          <description>Adult subjects (age 18-80) wear Guardian™ Sensor (3) over 7 days and participate in FSTs.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
        </group>
        <group group_id="P2">
          <title>Pediatric Subjects (Age 2-17) With Diabetes Wearing Guardian™ Sensor (3)</title>
          <description>Pediatric subjects (age 2-17) wear Guardian™ Sensor (3) over 7 days and participate in FSTs.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to complete study visits due to COVID-19</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics and other baseline characteristics were documented for eligible subjects (i.e., subjects who passed screening).</population>
      <group_list>
        <group group_id="B1">
          <title>Adult Subjects (Age 18-80) With Diabetes Wearing Guardian™ Sensor (3)</title>
          <description>Adult subjects (age 18-80) wear Guardian™ Sensor (3) over 7 days and participate in FSTs.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
        </group>
        <group group_id="B2">
          <title>Pediatric Subjects (Age 2-17) With Diabetes Wearing Guardian™ Sensor (3)</title>
          <description>Pediatric subjects (age 2-17) wear Guardian™ Sensor (3) over 7 days and participate in FSTs.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="169"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="311"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="17.8"/>
                    <measurement group_id="B2" value="10.9" spread="4.0"/>
                    <measurement group_id="B3" value="29.9" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Readings Within 20% Agreement</title>
        <description>Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values &lt; 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.</description>
        <time_frame>7 days (170 hours)</time_frame>
        <population>Subjects with at least 1 sensor-YSI (or sensor-SMBG for subjects 2-6 years) paired point during the sensor wear</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Subjects (Age 18-80) With Diabetes Wearing Guardian™ Sensor (3) on the Arm</title>
            <description>Adult subjects (age 18-80) wear Guardian™ Sensor (3) on the arm over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
          </group>
          <group group_id="O2">
            <title>Adult Subjects (Age 18-80) With Diabetes Wearing Guardian™ Sensor (3) on the Abdomen</title>
            <description>Adult subjects (age 18-80) wear Guardian™ Sensor (3) on the abdomen over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
          </group>
          <group group_id="O3">
            <title>Pediatric Subjects (Age 2-17) With Diabetes Wearing Guardian™ Sensor (3) on the Arm</title>
            <description>Pediatric subjects (age 2-17) wear Guardian™ Sensor (3) on the arm over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
          </group>
          <group group_id="O4">
            <title>Pediatric Subjects (Age 2-17) With Diabetes Wearing Guardian™ Sensor (3) on the Buttock</title>
            <description>Pediatric subjects (age 2-17) wear Guardian™ Sensor (3) on the buttock over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Readings Within 20% Agreement</title>
          <description>Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™*) reference value (within 20 mg/dL if sensor values &lt; 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.</description>
          <population>Subjects with at least 1 sensor-YSI (or sensor-SMBG for subjects 2-6 years) paired point during the sensor wear</population>
          <units>Percentage of Readings</units>
          <param>Mean</param>
          <dispersion>91.8% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.00" lower_limit="86.05" upper_limit="89.95"/>
                    <measurement group_id="O2" value="87.96" lower_limit="86.13" upper_limit="89.80"/>
                    <measurement group_id="O3" value="84.59" lower_limit="82.02" upper_limit="87.17"/>
                    <measurement group_id="O4" value="81.05" lower_limit="77.58" upper_limit="84.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.041</p_value>
            <method>ANCOVA</method>
            <method_desc>A generalized estimating equation model was used, considering correlation structure of day of sensor wear (1-7).</method_desc>
            <param_type>Intercept from ANCOVA as agreement rate</param_type>
            <param_value>88.00</param_value>
            <ci_percent>91.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.05</ci_lower_limit>
            <ci_upper_limit>89.95</ci_upper_limit>
            <estimate_desc>A group sequential study design was utilized to perform interim analysis. For the final stage, the p-value is 0.041.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.041</p_value>
            <method>ANCOVA</method>
            <method_desc>A generalized estimating equation model was used, considering correlation structure of day of sensor wear (1-7).</method_desc>
            <param_type>Intercept from ANCOVA as agreement rate</param_type>
            <param_value>87.96</param_value>
            <ci_percent>91.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.13</ci_lower_limit>
            <ci_upper_limit>89.80</ci_upper_limit>
            <estimate_desc>A group sequential study design was utilized to perform interim analysis. For the final stage, the p-value is 0.041.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANCOVA</method>
            <method_desc>A generalized estimating equation model was used, considering correlation structure of day of sensor wear (1-7).</method_desc>
            <param_type>Intercept from ANCOVA as agreement rate</param_type>
            <param_value>84.59</param_value>
            <ci_percent>91.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.02</ci_lower_limit>
            <ci_upper_limit>87.17</ci_upper_limit>
            <estimate_desc>A group sequential study design was utilized to perform interim analysis. For the final stage, the p-value is 0.041.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.041</p_value>
            <method>ANCOVA</method>
            <method_desc>A generalized estimating equation model was used, considering correlation structure of day of sensor wear (1-7).</method_desc>
            <param_type>Intercept from ANCOVA as agreement rate</param_type>
            <param_value>81.05</param_value>
            <ci_percent>91.8</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.58</ci_lower_limit>
            <ci_upper_limit>84.53</ci_upper_limit>
            <estimate_desc>A group sequential study design was utilized to perform interim analysis. For the final stage, the p-value is 0.041.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the course of the study, up to 91 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adult Subjects (Age 18-80) With Diabetes Wearing Guardian™ Sensor (3)</title>
          <description>Adult subjects (age 18-80) wear Guardian™ Sensor (3) over 7 days and participate in FSTs.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
        </group>
        <group group_id="E2">
          <title>Pediatric Subjects (Age 2-17) With Diabetes Wearing Guardian™ Sensor (3)</title>
          <description>Pediatric subjects (age 2-17) wear Guardian™ Sensor (3) over 7 days and participate in FSTs.&#xD;
Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter: Continuous Glucose Monitoring and frequent sample testing</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Medical device site bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Medical device site haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Insulin resistance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robin Mottackel</name_or_title>
      <organization>Medtronic Diabetes</organization>
      <phone>8185764886</phone>
      <email>robin.e.mottackel@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

